<DOC>
	<DOC>NCT01970033</DOC>
	<brief_summary>SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for 3 months</brief_summary>
	<brief_title>Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients diagnosed with type 2 diabetes mellitus Patients have treated with diet/exercise at least 3 months 7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after runin Patient has history of type 1 diabetes mellitus Patient has history of ketoacidosis Patient has history of severe unconscious hypoglycemosis Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg Patient has severe liver or kidney disease,alanine aminotransferase &gt;2×UNL, Aspartate Aminotransferase &gt;2×upper normal limit(UNL)；total bilirubin &gt;2×UNL； creatinine&gt;1.5 mg/dL (Male,132.6μmol/L) ，&gt;1.4 mg/dL(Female，123.8μmol/L) Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. ) Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on Patient has history of malignancy Patient has history of alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>SP2086</keyword>
	<keyword>Phase III</keyword>
	<keyword>Monotherapy</keyword>
</DOC>